Low-Dos Fisetin Supplementation och Its Association With Chronic Inflammation i Middle-Aged och Older Adults: Studie Protocol for a Triple-Blind, Randomised, Placebo-Kontrollerad Trial.

Tavenier et al. published a studie protocol for a triple-blind, randomiserad, placebokontrollerad trial of low-dos fisetin (100 mg orally once daily for 7 weeks) i middle-aged och older adults. The primär outcome is the between-group difference i change of plasma soluble urokinase plasminogen activator receptor (suPAR), a marker of chronic inflammation, från baseline till week 7. This is a protocol paper only — no results have been reported. Fisetin remains under clinical investigation as a senolytic och anti-inflammatory agent; the trial will add till the limited humana bevis base once completed.